A series of significant venture rounds last week pushed the money raised by private biotechs this year across the $5 billion mark, making it the 10th straight year in which the industry has crossed the threshold.

This year's money has already eclipsed the low water mark of the last decade, when only $5.1 billion was raised in 2010 (see "Making the Mark").